GGTI-2418

CAS No. 501010-06-6

GGTI-2418( —— )

Catalog No. M32935 CAS No. 501010-06-6

GGTI-2418 is a highly potent, competitive, and selective inhibitor of geranylgeranyltransferase I (GGTase I), exhibiting inhibitory activities with IC50 values of 9.5 nM for GGTase I and 53 μM for FTase, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 73 In Stock
5MG 107 In Stock
10MG 180 In Stock
25MG 342 In Stock
50MG 517 In Stock
100MG 711 In Stock
500MG 1503 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GGTI-2418
  • Note
    Research use only, not for human use.
  • Brief Description
    GGTI-2418 is a highly potent, competitive, and selective inhibitor of geranylgeranyltransferase I (GGTase I), exhibiting inhibitory activities with IC50 values of 9.5 nM for GGTase I and 53 μM for FTase, respectively.
  • Description
    GGTI-2418 is a highly potent, competitive, and selective geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-2418 inhibits GGTase I and FTase activities with IC50s of 9.5 nM and 53 μM, respectively. GGTI-2418 also increases p27(Kip1) and induces significant regression of breast tumors.
  • In Vitro
    GGTI-2418 inhibits GGTase I and FTase activities with IC50s of 9.5±2.0 nM and 53±11 μM, respectively, a 5,600-fold selectivity toward inhibition of GGTase I versus FTase. GGTI-2418 demonstrates competitive inhibition of GGTase I against the H-Ras-CVLL protein with a Ki of 4.4±1.6 nM.GGTi-2418 (10-15 μM; 16 hours) treatment delocalizes FBXL2 and stabilizes IP3R3.Western Blot Analysis Cell Line:HeLa cells Concentration:10-15 μM Incubation Time:16 hours Result:Delocalized FBXL2 and stabilized IP3R3.
  • In Vivo
    GGTI-2418 (100 mg/kg daily or 200 mg/kg every third day; 15 days) significantly inhibits the growth of breast tumor xenografts in nude mice with MDA-MB-231 xenografts.GGTI-2418 (100 mg/kg daily; 5 days) induces regression of ErbB2-driven mammary tumors in ErbB2 transgenic mice. GGTI-2418 inhibits the geranylgeranylation of Rap1 and causes a dramatic decrease in S473 phosphorylation of Akt. GGTI-2418 also upregulates p27 levels in vivo.Animal Model:Nude mice implanted with MDA-MB-231 breast cancer tumors Dosage:100 mg/kg daily or 200 mg/kg every third day Administration:Injected intraperitoneally; 15 days Result:Inhibited the growth of breast tumor xenografts.Animal Model:ErbB2 transgenic mice Dosage:100 mg/kg/day Administration:Subcutaneously; 5 days Result:Halted tumor growth and induced massive tumor regression. Tumor decreased by 76% following GGTI-2418 treatment.
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Transferase
  • Recptor
    Transferase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    501010-06-6
  • Formula Weight
    441.52
  • Molecular Formula
    C23H31N5O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (283.11 mM; Ultrasonic )
  • SMILES
    CC(C)C[C@H](NC(=O)N1CCN(Cc2nc[nH]c2C)C(=O)[C@@H]1Cc1ccccc1)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kazi A, et al. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol Cell Biol. 2009 Apr;29(8):2254-63.?
molnova catalog
related products
  • Ibiglustat (L-Malic ...

    Ibiglustat (L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase.

  • 3-Methoxybenzamide

    3-Methoxybenzamide is a competitive inhibitor of poly(ADP-ribose) synthetase.

  • CBHcy

    CBHcy is a dual-substrate analogue, a specific BHMT inhibitor that causes betaine-homocysteine S-methyltransferase (BHMT) to adopt the same conformation as the ternary complex, potentially inducing the development of cysteinemia.